Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. (February 2017) - Necchi, A.; Bellmunt, J.; De Wit, R.; Vaughn, D.; Fradet, Y.; Lee, J.L.; Fong, L.; Vogelzang, N.; Climent, M.; Petrylak, D.; Choueiri, T.; Gerritsen, W.; et al.